Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 2/20 | 0.56 |
| ▸ | CASP7 | P55210 | 2/20 | 0.56 |
| ▸ | CASP6 | P55212 | 2/20 | 0.56 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.56 |
| ▸ | CASP2 | P42575 | 1/20 | 0.56 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | CASP9 | P55211 | 1/20 | 0.44 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 3/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | FER | P16591 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalimide SCHEMBL27169395 | 1.00 | GSK3B (0.65) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL1001750 | 0.98 | GSK3B (0.68) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL14861040 | 0.91 | GSK3B (0.65) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL28810882 | 0.89 | GSK3B (0.75) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL28372975 | 0.89 | GSK3B (0.83) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL27772865 | 0.86 | GSK3B (0.79) | GSK3BCASP3CASP7CASP6CASP8 | |
| Piperidine SCHEMBL28277968 | 0.83 | PARP1 (0.71) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL29366030 | 0.81 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL64 | 0.81 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL30125197 | 0.81 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2001863-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | GSK3B 140/4885CASP3 2141/4885CASP7 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.